- Analysis: GSK gives few clues on plans to replenish medicine cabinet – PharmaLive PharmaLive
- Big pharma: GSK beats forecasts, but Novartis lags Reuters
- GSK Posts Higher Q4 Sales, Profits, With Record Sales From Shingles Vaccine Yahoo Finance
- GSK touts momentum for core products Cabenuva, Shingrix FiercePharma
- GSK delivers strong 2022 performance with full year sales of £29.3 billion +19% AER, +13% CER; Total EPS 371.4p >100% Adjusted EPS of 139.7p +27% AER, +15% CER from continuing operations GSK
- View Full Coverage on Google News
Read More: Analysis: GSK gives few clues on plans to replenish medicine cabinet – PharmaLive – PharmaLive